CANDEL THERAPEUTICS, INC. Interest and Other Income
CANDEL THERAPEUTICS, INC. (CADL) reported Interest and Other Income of $1.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. interest and other income for the quarter ending 2026-06-30 was $1.67M, a 80.56% increase year-over-year.
- CANDEL THERAPEUTICS, INC. interest and other income for the quarter ending 2026-03-31 was $1.32M, a 41.54% increase year-over-year.
- CANDEL THERAPEUTICS, INC. interest and other income for the quarter ending 2025-12-31 was $1.10M, a 280.00% increase year-over-year.
- CANDEL THERAPEUTICS, INC. interest and other income for the quarter ending 2025-09-30 was $953.00K, a 303.81% increase year-over-year.
- CANDEL THERAPEUTICS, INC. interest and other income for fiscal 2025 was $3.92M, a 260.50% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. interest and other income for fiscal 2024 was $1.09M, a 47.81% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. interest and other income for fiscal 2023 was $2.08M.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.67M 10-Q · filed 2026-08-13 | $2.99M 10-Q · filed 2026-08-13 | $4.10M derived: sum of 3 quarters · filed 2026-08-13 | $5.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.32M 10-Q · filed 2026-05-14 | $2.42M derived: sum of 2 quarters · filed 2026-05-14 | $3.38M derived: sum of 3 quarters · filed 2026-05-14 | $4.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.06M derived: sum of 2 quarters · filed 2026-03-12 | $2.98M derived: sum of 3 quarters · filed 2026-08-13 | $3.92M 10-K · filed 2026-03-12 |
| 2025-09-30 | $953.00K 10-Q · filed 2025-11-13 | $1.88M derived: sum of 2 quarters · filed 2026-08-13 | $2.81M 10-Q · filed 2025-11-13 | $3.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $926.00K 10-Q · filed 2026-08-13 | $1.86M 10-Q · filed 2026-08-13 | $2.15M derived: sum of 3 quarters · filed 2026-08-13 | $2.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $934.00K 10-Q · filed 2026-05-14 | $1.22M derived: sum of 2 quarters · filed 2026-05-14 | $1.46M derived: sum of 3 quarters · filed 2026-05-14 | $1.70M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $526.00K derived: sum of 2 quarters · filed 2026-03-12 | $766.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.09M 10-K · filed 2026-03-12 |
| 2024-09-30 | $236.00K 10-Q · filed 2025-11-13 | $476.00K derived: sum of 2 quarters · filed 2025-11-13 | $796.00K 10-Q · filed 2025-11-13 | $1.21M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $240.00K 10-Q · filed 2025-08-14 | $560.00K 10-Q · filed 2025-08-14 | $975.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.48M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $320.00K 10-Q · filed 2025-05-13 | $735.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.24M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $917.00K derived: sum of 2 quarters · filed 2025-03-13 | $2.08M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $502.00K 10-Q · filed 2024-11-14 | $1.67M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |